The University of Chicago is conducting a clinical trial testing whether partial pleurectomy and decortication can help relieve symptoms for mesothelioma patients whose cancer can’t be completely removed. If the results are positive, it will offer significantly improved quality of life, even when the rare, asbestos-related cancer is too advanced or inaccessible for curative surgery.
Mesothelioma Patients with Unresectable Disease May Benefit from Partial Surgery
Partial pleurectomy is a surgical procedure where part of the pleura, the lining of the lung cavity, is removed. Unlike more aggressive surgeries like extrapleural pneumonectomy (removing the entire lung) or complete pleurectomy/decortication, this limited approach focuses on symptom relief and quality of life.
The mesothelioma clinical trial is specifically enrolling patients with unresectable or borderline resectable epithelioid pleural mesothelioma confined to one side of the chest. Patients must have successfully completed at least six weeks of systemic chemotherapy or immunotherapy before qualifying for the surgical procedure.
Trial Measures Symptom Relief and Quality of Life After Limited Surgery
The clinical trial’s primary objective is to assess improvements in mesothelioma patients’ symptoms using the mesothelioma-specific Lung Cancer Symptom Scale Average Symptom Burden Index three months after they’ve had the procedure. Secondary outcomes include longitudinal quality of life evaluation, complication rates, time to resuming systemic therapy, and overall survival over two years of follow-up. Participants will complete questionnaires about their mesothelioma symptoms at certain times after surgery, allowing researchers to track whether the limited surgical approach improves breathing, reduces pain, decreases fluid buildup, and enhances overall quality of life for patients living with unresectable disease.
For mesothelioma patients facing unresectable disease, this clinical trial offers the possibility of symptom relief and quality of life improvement. For more information on the study, mesothelioma patients can contact PhaseIICRA@medicine.bsd.uchicago.edu or visit ClinicalTrials.gov, using identifier NCT07126509.
If you or someone you love has been diagnosed with mesothelioma, this type of innovative research holds the promise of better outcomes in the future. For more information on other resources, contact the Patient Advocates at Mesothelioma.net at 1-800-692-8608.
